Active — Not RecruitingNot Applicable

Individualized Targeting and Neuromodulation of Late-Life Depression

United States24 participantsStarted 2024-10-01

Plain-language summary

An open-label, single-arm, clinical research study about how to make transcranial magnetic stimulation (TMS), an FDA-approved treatment, more effective for patients with late-life depression using fMRI.

Who can participate

Age range60 Years – 79 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Participant must be at least 60 years of age (all genders, races, and ethnicities), and less than or equal to 79 years of age.
✓. Participant must have a diagnosis of major depressive disorder without psychosis for the past 6 months, as diagnosed by a board-certified psychiatrist
✓. Must show evidence of being in a current major depressive episode, as indicated by score on QIDS-C of 10 or higher.

Exclusion criteria

✕. Participant must be fluent in English
✕. Current diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, or any other psychotic disorder
✕. Substance use disorder, abuse or dependence, with active use within the last 3 months
✕. Legal or mental incompetency, or inability to consent to study
✕. Unstable medical illness, or hospitalization within 3 weeks of study entry
✕. Current diagnosis of a neurological disorder or neurocognitive disorder
✕. Prior neurosurgical procedure
✕. History of seizure

What they're measuring

Anterior Cingulate Cortex (ACC) Connectivity

Timeframe: Week 3 post-treatment assessment

Trial details

NCT IDNCT04543773

SponsorUniversity of New Mexico

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-07-01

View on ClinicalTrials.gov More Major Depressive Disorder trials